Literature DB >> 28807755

Antimicrobial susceptibility of pathogens in acute uncomplicated cystitis cases in the urology department of a community hospital in Japan: Comparison with treatment outcome and hospital-wide antibiogram.

Toshiki Etani1, Taku Naiki2, Sachiyo Yamaguchi3, Saori Mori4, Takashi Nagai5, Keitaro Iida6, Ryosuke Ando7, Noriyasu Kawai8, Keiichi Tozawa9, Tohru Mogami10, Takahiro Yasui11.   

Abstract

We hypothesized that cases of uncomplicated cystitis treated in a Urology Department would display higher antimicrobial susceptibility than those reported by the hospital antibiogram. This would suggest narrow spectrum antibiotics could still be an effective treatment for uncomplicated cystitis despite this era of antimicrobial resistance. The objective of this study was thus to evaluate the rates of antimicrobial susceptibility of isolates cultured from uncomplicated cystitis cases that presented to the Urology Department of a community hospital in Japan. We evaluated the efficacy of cefaclor, a narrow spectrum antibiotic, for uncomplicated cystitis. We further compared the rates of antimicrobial susceptibility of isolates from uncomplicated cystitis cases to those reported in a hospital-wide antibiogram. A retrospective chart review was performed of patients diagnosed with uncomplicated cystitis in the Urology Department. The patients were mainly treated orally by cefaclor at 750 mg/day for seven days. Significantly greater susceptibilities to cefazolin (87.0% vs 65.7%), trimethoprim-sulfamethoxazole (89.4% vs 79.1%) and levofloxacin (84.6% vs 66.9%) were observed in a cystitis antibiogram for Escherichia coli compared with a hospital-wide antibiogram. The clinical efficacy of cefaclor for acute cystitis was also demonstrated. The greater susceptibility of Escherichia coli to antimicrobials observed in this study supports the hypothesis that antimicrobial susceptibility rates in uncomplicated cystitis cases that present to the Urology Department would be greater than those reported in the hospital antibiogram. Therefore, uncomplicated acute cystitis can be treated by narrow spectrum antibiotics such as cefaclor even in this ''antimicrobial resistance era''.
Copyright © 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiogram; Cefaclor; Cystitis; Escherichia coli

Mesh:

Substances:

Year:  2017        PMID: 28807755     DOI: 10.1016/j.jiac.2017.07.011

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  5 in total

1.  Acute uncomplicated cystitis: is antibiotic unavoidable?

Authors:  Ekaterina Kulchavenya
Journal:  Ther Adv Urol       Date:  2018-06-20

2.  Cefaclor as a first-line treatment for acute uncomplicated cystitis: a retrospective single-center study.

Authors:  Dai Koguchi; Yasukiyo Murakami; Masaomi Ikeda; Masato Dobashi; Junichiro Ishii
Journal:  BMC Urol       Date:  2020-04-06       Impact factor: 2.264

3.  Antimicrobial prescription practices for outpatients with uncomplicated cystitis in Japan.

Authors:  Misa Takahashi; Hideharu Hagiya; Tsukasa Higashionna; Yasuhiro Nakano; Kota Sato; Yuto Haruki; Mai Haruki; Hiroyuki Honda; Hiroko Ogawa; Keigo Ueda; Fumio Otsuka
Journal:  Sci Rep       Date:  2022-04-08       Impact factor: 4.379

Review 4.  Developmental roadmap for antimicrobial susceptibility testing systems.

Authors:  Alex van Belkum; Till T Bachmann; Gerd Lüdke; Jan Gorm Lisby; Gunnar Kahlmeter; Allan Mohess; Karsten Becker; John P Hays; Neil Woodford; Konstantinos Mitsakakis; Jacob Moran-Gilad; Jordi Vila; Harald Peter; John H Rex; Wm Michael Dunne
Journal:  Nat Rev Microbiol       Date:  2019-01       Impact factor: 60.633

5.  Escherichia coli Resistance to Fluoroquinolones in Community-Acquired Uncomplicated Urinary Tract Infection in Women: a Systematic Review.

Authors:  Ann E Stapleton; Florian M E Wagenlehner; Aruni Mulgirigama; Monique Twynholm
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.